Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children

Torsak Bunupuradah, Passorn Punyahotra, Tim R Cressey, Amornrat Srimuan, Narukjaporn Thammajaruk, Jiratchaya Sophonphan, Chulalak Sriheara, David M Burger, Thanyawee Puthanakit, Jintanat Ananworanich, Torsak Bunupuradah, Passorn Punyahotra, Tim R Cressey, Amornrat Srimuan, Narukjaporn Thammajaruk, Jiratchaya Sophonphan, Chulalak Sriheara, David M Burger, Thanyawee Puthanakit, Jintanat Ananworanich

Abstract

Background: Abacavir and lamivudine are approved for once-daily use in HIV-infected adults. Limited pharmacokinetic (PK) data for abacavir and lamivudine in children are available.

Methods: A crossover study to compare PK of once- versus twice-daily abacavir and lamivudine was conducted in virologically suppressed HIV-infected Thai children aged <18years, with bodyweight of at least 14 kg, HIV RNA <50 copies/mL and HLA-B*5701 negative. Abacavir and lamivudine daily doses by bodyweight were 300 and 150 mg for 14-<20 kg, 450 and 300 mg for 20-<25 kg, and 600 and 300 mg for ≥25 kg, respectively. Originator abacavir and lamivudine scored tablets were administered. Intensive PK sampling was performed after 14 days of each dose. PK parameters were determined using non-compartmental analysis.

Results: Thirty children (57% male) were enrolled, 10 per weight band. Median (IQR) age was 8.8 (6.6-11.3) years and bodyweight was 21.9 (19.2-30.6) kg. The geometric means (GM) AUC0-24 of once- and twice-daily abacavir were 14.43 and 10.65 mg.h/L, respectively. The geometric mean ratio (GMR) of AUC0-24 for once- versus twice-daily abacavir dosing was 1.36 [90% confidence interval (CI) 1.11-1.66]. The GM AUC0-24 of once- and twice-daily lamivudine were 17.70 and 18.11 mg.h/L, respectively. The GMR of AUC0-24 for once- versus twice-daily lamivudine dosing was 0.98 (90% CI 0.84-1.14). At 96 weeks, 90% had HIV RNA <50 copies/mL and there were no serious adverse events.

Conclusion: Abacavir exposure was greater with once-daily dosing, while lamivudine once- and twice-daily exposures were bioequivalent. Once-daily abacavir and lamivudine using weight-band dosing is a treatment option for children.

Keywords: HIV-infected children; abacavir; lamivudine; once-daily; pharmacokinetics.

Figures

Figure 1.
Figure 1.
Mean plasma concentration of (a) abacavir and (b) lamivudine

References

    1. UNAIDS Report on the Global AIDS Epidemic 2013. Available at: ( accessed May 2015).
    1. Maitland D, Jackson A, Osorio J et al. . Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy. HIV Med 2008; 9: 667– 672.
    1. LePrevost M, Green H, Flynn J et al. . Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children. Pediatr Infect Dis J 2006; 25: 533– 537.
    1. Musiime V, Kendall L, Bakeera-Kitaka S et al. . Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial. Antivir Ther 2010; 15: 1115– 1124.
    1. WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2013. Available at: ( accessed May 2015).
    1. Podzamczer D, Ferrer E, Sanchez P et al. . Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007; 44: 139– 147.
    1. Bergshoeff A, Burger D, Verweij C et al. . Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Antivir Ther 2005; 10: 239– 246.
    1. Paediatric European Network for Treatment of AIDS (PENTA) Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3–<36 months. Antivir Ther 2010; 15: 297– 305.
    1. Chokephaibulkit K, Cressey TR, Capparelli E et al. . Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. Antivir Ther 2011; 16: 1287– 1295.
    1. Vanprapar N, Cressey TR, Chokephaibulkit K et al. . A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand. Pediatr Infect Dis J 2010; 29: 940– 944.
    1. Lugt J, Avihingsanon A.. Clinical pharmacology and pharmacokinetics of antiretrovirals in Asia. Asian Biomed 2009; 3: 53– 62.
    1. Avihingsanon A, Lugt J, Kerr SJ et al. . A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults. Clin Pharmacol Ther 2009; 85: 402– 408.
    1. National Institute of Allergy and Infectious Disease Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events version 1.0, December 2004; clarification August 2009 Available at: ( accessed May 2015).
    1. WHO Antiretroviral therapy for HIV infection in infants and children: towards universal access: recommendations for a public health approach 2010 revision. 2010. Available at: ( accessed June 2015)
    1. Holland DT, DiFrancesco R, Connor JD, Morse GD.. Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring. Ther Drug Monit 2006; 28: 367– 374.
    1. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Bioavailability and Bioequivalence Studies for Orally Administered Drug Products: General Considerations March 2003. BP Revision 1 Updated March 2003 Available at: ( accessed July 2012).
    1. Grundy SM, Cleeman JI, Daniels SR et al. . Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735– 2752.
    1. Yuen GJ, Weller S, Pakes GE.. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet 2008; 47: 351– 371.
    1. Waters LJ, Moyle G, Bonora S et al. . Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Antivir Ther 2007; 12: 825– 830.
    1. Moyle G, Boffito M, Fletcher C et al. . Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2009; 53: 1532– 1538.
    1. Technau KG, Schomaker M, Kuhn L et al. . Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysis. Pediatr Infect Dis J 2014; 33: 617– 622.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera